Dr. Bart Barlogie is synonymous with myeloma treatment approach that hits the diseases hard on right at the beginning with intense treatment with multi drugs, transplants, consolidation, and maintenance to keep it under control. Dr. Barlogie is Founder & Director, Myeloma Institute at UAMS, Little Rock and is considered to be one of the best myeloma experts one could get treated under if diagnosed.
Arecent article on Dr. Barlogie outlined the achievements of UAMS-MIRT under Dr. Barlogie and I was impressed. I bullet them down here:
- UAMS-MIRT has grown to be the largest research and care center focusing on multiple myeloma and related disorders in the US.
- The institute has seen more than 10,000 patients from every state in the United States and more than 50 foreign countries
- Performed more than 9,000 peripheral blood stem cell transplants
- First center of its kind to use tandem bone marrow/peripheral blood stem cell transplants
- First to perform transplants on an outpatient basis
- First to safely transplant patients age 70 and above
- First to transplant patients with renal disease
- First to introduce thalidomide as anti-angiogenesis therapy
Highlight of all achievements: 57 percent of the center’s newly diagnosed patients lived five years or more, compared to that of 34 percent nationally, according to a SEER Program report by the National Cancer Institute.
Read the article on Dr. Barlogie here. And I loved the picture…I am reposting it here…
You can also read about Dr. Barlogie’s survival data on our CurePanel co-host and UAMS patient, Gary Petersen’s site, myelomasurvival.com. (Scroll down to Southern Region) and a look at TT3 myeloma survival data here.
Below is a brief bio of Dr. Bart Barlogie:
Dr. Barlogie is Director of the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas. He also is Madge Simmons Professor of Cancer Research.
Dr. Barlogie received his medical degree from Heidelberg University, Germany, and his research degree from the Max Planck Institute for Medical Research, also in Heidelberg. He continued his postgraduate clinical training at the University of Munich, The University of Münster, and the M.D. Anderson Hospital and Tumor Institute in Houston, Texas.
Dr. Barlogie held numerous professional appointments at M.D. Anderson Hospital and Tumor Institute, the University of Texas Medical School at Houston, and the University of Texas at Houston. In addition to his current appointments at the University of Arkansas, he still holds an Adjunct Professor of Medicine (Hematology) position at M.D. Anderson Hospital and Tumor Institute.
Not only is Dr. Barlogie a prolific author; having written or contributed to several hundred journal articles, abstracts, and book chapters, he is also a noted presenter in the fields of hematology and oncology. Dr. Barlogie holds/has held editorial board positions on the following journals: Cell and Tissue Kinetics, Cytometry , Clinical Cancer Research,Annals of Hematology and Blood.
- Dr. Barlogie From UAMS: "Revlimid Does Not Cause Secondary Cancer."
- Can UAMS Total Therapy cure myeloma patients? Stay tuned!
- University Of Arkansas Medical Sciences (UAMS) Multiple Myeloma Patient Survivor Stories
- Multiple Myeloma Specialist Dr. James Berenson will discuss Multiple Myeloma disease control Without Transplant on the Myeloma Cure Panel 11/29/2012 Broadcast
- University of Arkansas Treats Ten Thousandth Multiple Myeloma Patient